© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
December 23, 2022
In the pivotal phase 2 GO29781 study, the objective response rate and response durability was high, leading to the FDA approval of mosunetuzumab for the treatment of relapsed or refractory follicular lymphoma.
December 12, 2022
Phase 2 study results show the durability of response associated with mosunetuzumab in patients with relapsed or refractory follicular lymphoma.
December 11, 2022
Christopher J. Melani, MD, discusses the combination regimen from the ViPOR study evaluating patients with aggressive lymphomas.
December 02, 2022
Closing out their discussion on bispecific antibody therapies, Matthew Matasar, MD and Laurie Sehn, MD, consider ongoing clinical trials and real-world use of these novel agents.
Experts Matthew Matasar, MD and Laurie Sehn, MD, nuance the adverse event profiles of bispecific antibody therapies and consider how these will help inform treatment decisionmaking.
Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.
Shared insight on the development and use of CAR T-cell therapy in patients with multiply relapsed follicular lymphoma.
Switching to the paradigm of multiply relapsed follicular lymphoma, expert participants discuss the rationale behind and use of PI3k- and EZH2- targeted therapies.
Matthew Matasar, MD and Laurie Sehn, MD, share insight on available therapies for relapsed or refractory follicular lymphoma and reflect on factors that help in treatment selection.
Centering discussion on both symptomatic and asymptomatic disease, expert participants highlight cornerstone frontline therapies in follicular lymphoma.